Dan Leonard
Stock Analyst at UBS
(3.57)
# 863
Out of 5,237 analysts
297
Total ratings
48.26%
Success rate
5.94%
Average return
Main Sectors:
Stocks Rated by Dan Leonard
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BRKR Bruker | Maintains: Neutral | $40 → $45 | $43.27 | +4.00% | 13 | May 7, 2026 | |
| DHR Danaher | Maintains: Buy | $270 → $250 | $166.52 | +50.13% | 19 | Apr 22, 2026 | |
| A Agilent Technologies | Maintains: Buy | $180 → $165 | $111.46 | +48.04% | 24 | Feb 26, 2026 | |
| RGEN Repligen | Maintains: Buy | $200 → $195 | $115.91 | +68.23% | 2 | Feb 25, 2026 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $170 → $175 | $168.46 | +3.88% | 7 | Feb 25, 2026 | |
| TXG 10x Genomics | Maintains: Neutral | $14 → $20 | $20.50 | -2.44% | 8 | Feb 20, 2026 | |
| WAT Waters | Maintains: Neutral | $395 → $370 | $348.07 | +6.30% | 13 | Feb 10, 2026 | |
| IQV IQVIA Holdings | Maintains: Buy | $280 → $240 | $173.55 | +38.29% | 19 | Feb 6, 2026 | |
| TECH Bio-Techne | Maintains: Buy | $70 → $79 | $47.42 | +66.60% | 13 | Feb 5, 2026 | |
| GH Guardant Health | Maintains: Buy | $80 → $110 | $96.71 | +13.74% | 11 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $500 → $590 | $452.60 | +30.36% | 18 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $5.13 | +192.40% | 10 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $300 → $305 | $417.29 | -26.91% | 2 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1,530 → $1,350 | $1,078.53 | +25.17% | 9 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $355 → $310 | $243.79 | +27.16% | 20 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $355 → $310 | $255.54 | +21.31% | 20 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $145 → $115 | $98.95 | +16.22% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $122 → $99 | $108.70 | -8.92% | 1 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $25 | $7.97 | +213.68% | 7 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $9 | $13.17 | -31.66% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $15.82 | +121.24% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $200 | $142.51 | +40.34% | 16 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $11 | $4.74 | +132.07% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $70 | $199.14 | -64.85% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $7 | $13.54 | -48.30% | 2 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $260 | $118.96 | +118.56% | 5 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $160 → $145 | $189.81 | -23.61% | 10 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $59 → $61 | $32.63 | +85.78% | 3 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $330 → $340 | $255.08 | +33.29% | 11 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $18.28 | +31.29% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $45 → $35 | $4.21 | +731.35% | 12 | Aug 14, 2019 |
Bruker
May 7, 2026
Maintains: Neutral
Price Target: $40 → $45
Current: $43.27
Upside: +4.00%
Danaher
Apr 22, 2026
Maintains: Buy
Price Target: $270 → $250
Current: $166.52
Upside: +50.13%
Agilent Technologies
Feb 26, 2026
Maintains: Buy
Price Target: $180 → $165
Current: $111.46
Upside: +48.04%
Repligen
Feb 25, 2026
Maintains: Buy
Price Target: $200 → $195
Current: $115.91
Upside: +68.23%
Charles River Laboratories International
Feb 25, 2026
Maintains: Neutral
Price Target: $170 → $175
Current: $168.46
Upside: +3.88%
10x Genomics
Feb 20, 2026
Maintains: Neutral
Price Target: $14 → $20
Current: $20.50
Upside: -2.44%
Waters
Feb 10, 2026
Maintains: Neutral
Price Target: $395 → $370
Current: $348.07
Upside: +6.30%
IQVIA Holdings
Feb 6, 2026
Maintains: Buy
Price Target: $280 → $240
Current: $173.55
Upside: +38.29%
Bio-Techne
Feb 5, 2026
Maintains: Buy
Price Target: $70 → $79
Current: $47.42
Upside: +66.60%
Guardant Health
Oct 30, 2025
Maintains: Buy
Price Target: $80 → $110
Current: $96.71
Upside: +13.74%
Oct 23, 2025
Maintains: Neutral
Price Target: $500 → $590
Current: $452.60
Upside: +30.36%
Aug 7, 2025
Maintains: Buy
Price Target: $18 → $15
Current: $5.13
Upside: +192.40%
Jul 29, 2025
Downgrades: Sell
Price Target: $300 → $305
Current: $417.29
Upside: -26.91%
May 20, 2025
Upgrades: Buy
Price Target: $1,530 → $1,350
Current: $1,078.53
Upside: +25.17%
May 2, 2025
Maintains: Buy
Price Target: $355 → $310
Current: $243.79
Upside: +27.16%
May 2, 2025
Maintains: Buy
Price Target: $355 → $310
Current: $255.54
Upside: +21.31%
May 1, 2025
Upgrades: Buy
Price Target: $145 → $115
Current: $98.95
Upside: +16.22%
Apr 7, 2025
Maintains: Overweight
Price Target: $122 → $99
Current: $108.70
Upside: -8.92%
Jan 17, 2025
Downgrades: Neutral
Price Target: $29 → $25
Current: $7.97
Upside: +213.68%
Oct 18, 2024
Maintains: Neutral
Price Target: $7 → $9
Current: $13.17
Upside: -31.66%
Dec 7, 2023
Initiates: Neutral
Price Target: $35
Current: $15.82
Upside: +121.24%
Aug 10, 2023
Maintains: Neutral
Price Target: $225 → $200
Current: $142.51
Upside: +40.34%
Aug 8, 2023
Maintains: Neutral
Price Target: $14 → $11
Current: $4.74
Upside: +132.07%
Aug 4, 2023
Reiterates: Outperform
Price Target: $70
Current: $199.14
Upside: -64.85%
Feb 15, 2023
Reiterates: Underperform
Price Target: $7
Current: $13.54
Upside: -48.30%
Aug 25, 2022
Initiates: Neutral
Price Target: $260
Current: $118.96
Upside: +118.56%
Feb 4, 2022
Maintains: Equal-Weight
Price Target: $160 → $145
Current: $189.81
Upside: -23.61%
Dec 14, 2021
Maintains: Equal-Weight
Price Target: $59 → $61
Current: $32.63
Upside: +85.78%
Dec 14, 2021
Maintains: Overweight
Price Target: $330 → $340
Current: $255.08
Upside: +33.29%
Aug 10, 2021
Initiates: Overweight
Price Target: $24
Current: $18.28
Upside: +31.29%
Aug 14, 2019
Maintains: Hold
Price Target: $45 → $35
Current: $4.21
Upside: +731.35%